# Panitumumab

Panitumumab (Vectibix, Amgen Europe B.V.) has 3 EU-approved indications in 1 tumour type.

## Approved indications

### Colorectal cancer

| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Wild-type RAS | + FOLFOX or FOLFIRI | 1st line, metastatic | - |
| Wild-type RAS | + FOLFIRI | 2nd line, metastatic | After first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) |
| Wild-type RAS | Monotherapy | 3rd line+, metastatic | Failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens |

## Products

### Vectibix

- Company: Amgen Europe B.V.
- Target: EGFR-directed monoclonal antibody
- Class: EGFR (epidermal growth factor receptor) inhibitors
- ATC: L01FE02
- EU approval: 3 Dec 2007
- Label revised: 7 May 2025
- SmPC (EN): https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf
- Fachinformation (DE): https://www.ema.europa.eu/de/documents/product-information/vectibix-epar-product-information_de.pdf
- EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix

Mechanism (SmPC section 5.1): Panitumumab binds to the ligand-binding domain of EGFR, inhibiting ligand-induced receptor autophosphorylation and cell growth, while inducing receptor internalization and apoptosis.

## Label wording

- **Panitumumab** (Vectibix), Colorectal cancer, 1st line, metastatic: “in first-line in combination with FOLFOX or FOLFIRI.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf)
- **Panitumumab** (Vectibix), Colorectal cancer, 2nd line, metastatic: “in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf)
- **Panitumumab** (Vectibix), Colorectal cancer, 3rd line+, metastatic: “as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/drugs/panitumumab